NALIRIFOX

DRUG10 trials

Conditions

Basal Cell NeoplasmBiliary Tract Cancer (BTC)Colorectal CancerColorectal Cancer (CRC)Gastric or Gastroesophageal Junction AdenocarcinomaMetastatic Pancreatic CancerNENSPancreatic Adenocarcinoma

Phase 1

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

RecruitingNCT05482893

Phanes TherapeuticsBiliary Tract Cancer (BTC), Colorectal Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma +1

Start: 2023-03-15End: 2028-04-01Target: 350Updated: 2026-09-28

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

RecruitingNCT06483555

UNC Lineberger Comprehensive Cancer CenterBasal Cell Neoplasm, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma

Start: 2025-02-06End: 2027-08-01Target: 104Updated: 2026-04-23

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Active, not recruitingNCT06736717

University of Kansas Medical CenterPancreatic Cancer

Start: 2025-02-17End: 2027-01-01Updated: 2026-09-25

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

RecruitingNCT07030283

University of Colorado, DenverPancreatic Ductal Adenocarcinoma (PDAC)

Start: 2025-12-31End: 2030-07-01Target: 10Updated: 2026-02-02

Phase 2

A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

RecruitingNCT05851924

Memorial Sloan Kettering Cancer CenterPancreatic Ductal Adenocarcinoma

Start: 2023-05-12End: 2027-09-01Target: 60Updated: 2026-09-17

Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial

RecruitingNCT06816914

Taichung Veterans General HospitalResectable Pancreatic Adenocarcinoma

Start: 2025-03-05End: 2028-02-05Target: 84Updated: 2025-02-20

NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial

RecruitingNCT07077551

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNENS

Start: 2025-04-22End: 2028-12-31Target: 28Updated: 2025-07-22

Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

RecruitingNCT07163273

Northwell HealthPancreatic Ductal Adenocarcinoma

Start: 2025-06-26End: 2027-06-20Target: 41Updated: 2026-09-25

Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer

Not yet recruitingNCT07827053

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicinePancreatic Ductal Adenocarcinoma (PDAC)

Start: 2026-09-01End: 2030-09-01Target: 36Updated: 2026-09-18

Phase 4

Neoadjuvant Therapy （NALIRIFOX） for Locally Advanced Colon and Upper Rectal Cancer

Active, not recruitingNCT07020468

Affiliated Cancer Hospital of Shantou University Medical CollegeColorectal Cancer (CRC)

Start: 2025-05-15End: 2027-05-31Target: 57Updated: 2025-06-13

Related Papers

Spevatamig (PT886), a claudin 18.2 (CLDN18.2)/CD47 bispecific antibody, in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).

Journal of Clinical Oncology2026-05-27

Phase 1/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).

Journal of Clinical Oncology2026-01-10

A phase 1b/2 trial of onvansertib in combination with NALIRIFOX for first line treatment of advanced pancreatic cancer (PANCONVA trial).

Journal of Clinical Oncology2025-05-28